Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237272 | 0.76 | KDM4E (0.37) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1024102 | 0.70 | — | — | |
| SCHEMBL17456066 | 0.70 | CTSS (0.46) | — | |
| SCHEMBL17641539 | 0.69 | MEN1 (0.34) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL8306256 | 0.68 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL2499845 | 0.67 | MEN1 (0.37) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL4077595 | 0.67 | SMN1; SMN2 (0.40) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL2772096 | 0.67 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL8309426 | 0.66 | CYP3A4 (0.42) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL14265339 | 0.66 | KDM4E (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | MEN1 4142/4885HTT 3782/4885KMT2A 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.